by Jeito Life | 15 Jun Tue | English
Jeito Capital selects Alentis Therapeutics as its fifth investment since launching the fund Alentis is focused on the development of breakthrough treatments for fibrotic diseases and associated cancers Paris, France, 15 June 2021 – Jeito Capital (“Jeito”), a rapidly...
by Jeito Life | 27 May Thu | English
Jeito selects Pulmocide as its fourth investment since launching the fund Pulmocide is a clinical-stage biopharma company focused on the development of novel treatments for life-threatening respiratory diseases Paris, France, 27 May 2021 – Jeito Capital (“Jeito”), a...
by Jeito Life | 26 Jan Tue | English
The investment fund confirms the strength of its investment model in medical innovation, closing 2020 and celebrating its one-year anniversary with more than €250 million under management and first three investments. Paris, January 26th, 2021 – One year after...
by Jeito Life | 14 Dec Mon | English
Jeito’s third international investment in H2 2020, with deep and rapidly accelerating pipeline Therachon’s Founder, Elvire Gouze, launches latest new gene therapy company in her field of excellence €20 million Series A financing, sees Jeito co-investing again with...
by Jeito Life | 13 Nov Fri | English
Paris, France, 13 November 2020 – Jeito Capital (“Jeito”), a rapidly emerging independent investor dedicated to biotech and biopharma, today announced that Sanofi has made a €50 million investment in Jeito Capital. The investment will be deployed by Jeito’s highly...
by Jeito Life | 21 Oct Wed | English
Jeito Capital has selected SparingVision as its first French investment following the fund I launch in January 2020 SparingVision is focused on the discovery and development of innovative therapies for the treatment of blinding inherited retinal diseases Paris,...
Recent Comments